Andera Partners
VC Fund
Paris, France
Andera Partners is a VC fund in Paris focused on Biotechnology and Health Care. Andera Partners, formerly known as Edmond de Rothschild Investment Partners (EdRIP) As heir to the traditions and values that have ensured the success of the Rothschild family for 250 years, the Edmond de Rothschild Group has established itself over time as a leading player in European finance. Its activities are grouped around two major areas:Private Banking and Asset Management. The Group offers wealthy families, entrepreneurs, and large institutions a full range of solutions combining a culture of tailored solutions, stability, performance, and innovation. The Edmond de Rothschild Group’s offering is characterised by strong convictions, with the desire to guarantee to each of its customers: A unique, close relationship, underpinned by the know-how and the variety of expertise of a large international group; Autonomous, experienced teams, who anticipate economic trends and innovate to establish long-term performance; The recognised stability, strength, and independence of a family-owned financial group. Founded by Baron Edmond de Rothschild in 1953, the Group has been chaired by his son, Baron Benjamin de Rothschild, since 1997.
- Total investments:
- 185
- Last investment:
- Lead investor:
- 42%
- Fund size:
- $466M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Andera Partners invests in
Stages Andera Partners invests in
Countries Andera Partners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $7M–$83M
- Series B
- $14M–$85M
- Private Equity
- $110M–$237M
Investment Focus
Industry
- Biotechnology 55 (30%)
- Health Care 49 (26%)
- Medical 31 (17%)
- Therapeutics 22 (12%)
- Medical Device 20 (11%)
Stage
- Series B 38 (21%)
- Private Equity 33 (18%)
- Series A 28 (15%)
- Series C 22 (12%)
- Funding Round 21 (11%)
Country
- France 72 (39%)
- United States 20 (11%)
- Germany 9 (5%)
- Belgium 5 (3%)
- Switzerland 5 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
François Boudreault
Censor
|
Censor | Total investments: 1 | Find email | |
Francois Xavier Mauron
Partner
|
Partner | Total investments: 1 | Find email | |
Gilles Nobecourt
Partner
|
Partner | Total investments: 5 | Find email | |
Guillem Laporta
Analyst
|
Analyst | Total investments: 3 | Find email | |
Jan Van den Bossche
Partner
|
Partner | Total investments: 4 | Find email | |
| See all 25 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Cyllene Therapeutics
|
EG 427 is a French biotechnology company that pioneers a new approach in gene therapy called pinpoint gene therapy. | $37.7M / Series C / Jul 07, 2026 | |
Inventiva Pharma
|
Inventiva Pharma is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical needs in the areas of fibrosis, lysosomal storage disorders and oncology.They have built a pipeline backed by a discovery engine with an extensive library ofproprietary molecules, a wholly-owned research and development facility and a team with significant expertise and deep experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging these assets and expertise, they are advancing two clinical candidates in three indications, as well as a deep pipeline of earlier stage programs. | $120M / Post-IPO Equity / Jun 02, 2026 | |
Rivermark Medical
|
Rivermark Medical develops a minimally-invasive treatment for Benign Prostatic Hyperplasia (BPH) that restores urinary function. Developed by urologists to reliably reduce BPH symptoms with minimal side effects. | $20M / Series D / May 13, 2026 | |
exceet Card Group
|
exceet Card Group provides plastic, RFID, dual-interface, and chip cards for banking, government, transportation, access, and loyalty. Their competencies include design, development, consulting, production, customization, and letter shop. | Debt Financing / Feb 19, 2026 | |
Exciva
|
exciva is a Provider of targeted drug rescue program intended to involve pharmaceutical research and development based in Heidelberg, Germany. The company's program has been formulated for developing symptomatic and disease-modifying treatments, therapies, cures, prophylactics, supplements, formulations and methods of making and using suchcompositions, enabling the healthcare industry to access their program for rescuing and reusing approved drugs for new indications and new uses. | $62.2M / Series B / Jan 20, 2026 | |
|
Exciva
|
exciva is a Provider of targeted drug rescue program intended to involve pharmaceutical research and development based in Heidelberg, Germany. The company's program has been formulated for developing symptomatic and disease-modifying treatments, therapies, cures, prophylactics, supplements, formulations and methods of making and using suchcompositions, enabling the healthcare industry to access their program for rescuing and reusing approved drugs for new indications and new uses. | $62.2M / Series B / Jan 20, 2026 | |
Alveus Therapeutics
|
Alveus Therapeutics is a clinical-stage biotech company developing therapies for obesity and metabolic diseases. | $197M / Series A / Jan 08, 2026 | |
Spiro Medical
|
Spiro Medical is a medical device company developing a groundbreaking Pulmonary Neuromodulation (PNM) System for asthma treatment. The company offers a drug-free approach to controlling severe, chronic airway diseases through its Spiro Neuromodulation System. | $67M / Series A / Jan 07, 2026 | |
TargED Biopharmaceuticals
|
TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis. | $25.3M / Series A / Dec 16, 2025 | |
Artios Pharma
|
Artios is an independent DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. Established in May 2016, the Company is led by an experienced scientific and leadership team with proven expertise in DDR drug discovery. Artios is building a pipeline of next-generation DDR programs, including through a uniquepartnership with Cancer Research Technology (CRT), the development and commercialization arm of Cancer Research UK (CRUK), and with leading DNA repair researchers worldwide. The Company’s investors include SV Life Sciences, Merck Ventures, Imperial Innovations, Arix Bioscience PLC, CRT Pioneer Fund (managed by Sixth Element Capital), and AbbVie Ventures. Artios is based at the Babraham Institute in Cambridge, UK. | $115M / Series D / Nov 17, 2025 | |
| See all 185 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Andera Partners invest in?
Andera Partners invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Private Equity stage. Most of the 185 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Andera Partners's check size?
Andera Partners typically joins rounds of $7M–$83M at Series A, $14M–$85M at Series B and $110M–$237M at Private Equity. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Andera Partners participates in.
How do I contact Andera Partners?
Public channels for Andera Partners include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Andera Partners?
The team at Andera Partners includes François Boudreault (Censor), Francois Xavier Mauron (Partner) and Gilles Nobecourt (Partner), among 25 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
